Safety of Xiaflex® (Collagenase Clostridium histolyticum) Treatment for Adult Anterior Urethral Stricture Disease.
anterior urethral stricture
cch
collagenase
collagenase clostridium histolyticum
intralesional cch
urethral stricture
urethroplasty
xiaflex
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
11
09
2023
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
Male urethral stricture disease is highly prevalent and difficult to treat due to potential complications. Minimally invasive treatments tend to have high recurrence rates, keeping urethroplasty as the gold standard. Collagenase Clostridium histolyticum (CCH) has been used in humans to treat fibrosis in a minimally invasive manner. Herein, we present the preliminary results from treatments of three males with urethral stricture as a feasibility and safety evaluation of the first-in-human CCH treatment for male urethral stricture disease.
Identifiants
pubmed: 37829978
doi: 10.7759/cureus.45051
pmc: PMC10566641
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e45051Informations de copyright
Copyright © 2023, Wiegand et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Endourol. 2014 Aug;28(8):962-8
pubmed: 24745607
Urology. 2015 Sep;86(3):647.e1-6
pubmed: 26126692
BJU Int. 2007 Aug;100(2):397-402
pubmed: 17617144
Infect Dis Clin North Am. 2016 Dec;30(4):869-885
pubmed: 27816141
BJU Int. 2004 Nov;94(7):1037-9
pubmed: 15541123